NOV: Stifel Keeps Buy Rating, PT Raised to $21 from $19.

Bloomberg Expert: NOV's 15min Chart Shows Bollinger Bands Narrowing, KDJ Death Cross

NOV Q4 revs up 5% to $2.28 bln, FY22 net income $145 mln.

Barclays Upgrades NOV Inc. to Equal Weight with $20 Price Target Amid New CEO's Portfolio Repositioning Efforts

Barclays Upgrades NOV to Equal-Weight, Raises PT to $20 from $15.

Catalyst<ul> <li>Bullish signals are obviously dominant with three bullish technical indicators (3 bullish vs 0 bearish) in the last five days.</li> <li>Recent Bullish Engulfing and MACD Golden Cross patterns suggest strong upward momentum for NOV.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li> <li>Fund flow analysis indicates negative net inflow across all order sizes, suggesting investor caution.</li> <li>Analyst rating for NOV is currently Neutral, with market expectations trending pessimistic and analysts showing differing views.</li></ul>

Key Factors

NOV Q4 2025 adjusted earnings of 2 cents per share missed the Zacks Consensus Estimate of 25 cents and declined from 41 cents in the prior year.NOV reported Q4 revenues of $2.28 billion, a 5% increase, with FY22 full-year revenues totaling $8.74 billion.Barclays upgraded NOV Inc. to Equal Weight with a $20 price target, citing the new CEO's portfolio repositioning efforts.NOV swung to a $81 million fiscal 2025 Q4 net loss, reversing from a $161 million profit the previous year.Stifel maintained a Buy rating on NOV and raised its price target to $21 from $19.

NOV News